(Updated - April 30, 2018 4:18 PM EDT)

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today reported ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Hot Corp. News Hot FDA News Management Comments Trading Halts

Karyopharm Therapeutics (KPTI) PT Raised to $21 at WedbushMay 1, 2018 9:59 AM Karyopharm Therapeutics (KPTI) PT Raised to $24 at RBC Capital; 'We Would Be Buyers'May 1, 2018 7:58 AM Karyopharm Therapeutics (KPTI) to Resume Trading at 4:35 pm ETApril 30, 2018 4:16 PM Karyopharm Announces Positive Top-Line Data from Phase 2b STORM Study Evaluating Selinexor in Patients with Penta-Refractory Multiple MyelomaApril 30, 2018 4:05 PM